10 studies found

To describe the scale-up of MSF-OCA medical and humanitarian response for survivors of sexual violence and intimate partner violence and changes to SGBV care seeking behavior over time during 2017-2023. This internal descriptive analysis will help inform program approaches as well as advocacy. We will be able to highlight the gaps to include survivor participation in the advocacy plan. It may also add as useful data to triangulate with other knowledge generated from recent studies and assessments on survivor needs and care in the region.

To estimate the crude mortality rate for the total population (host and IDP) and for children under five years of age in the health zone of Fizi, South Kivu, DRC, in order to understand the current health status of the population in this catchment area.

To guide MSF programming and advocacy in the following ways: - Estimating the under 5 mortality rate and crude mortality rate. - The nutrition data will provide prevalence data that will help to confirm the scope of the nutrition crises and guide MSF OCA in making decisions about the ongoing response. Coverage of the current program will also be assessed. - The main causes of death and measles vaccination coverage will also help medical programming.

The purpose of the study is to assess the operational impact, feasibility, and acceptability, of the rollout of R21 malaria vaccine (children 5-36 months), and age-targeted intermittent preventative treatment in children (IPTc) with Dihydroartemisinin-Piperaquine (DHA-PQ) (children aged 3-59 months) as additional components to the existing malaria prevention package in Kule refugee camp where malaria incidence remains high despite vector control measures. Additionally, this study seeks to add to the knowledge base of extending malaria control interventions to new contexts, since existing evidence combining malaria vaccines, which protect against only P. falciparum infections, with chemoprevention programmes have only integrated with Seasonal Malaria Chemoprevention (SMC.) Hence this study will also provide understanding of the impact of combining an Artemisinin Combination Treatment (ACT) with a long half-life (DHA-PQ) which is effective against both P. falciparum (Pf) and Plasmodium vivax (Pv), alongside the R21 vaccine, thereby giving longer-lasting protection against Pf infections in a region prone to outbreaks.

The purpose of the study is to estimate the vaccination coverage in the target population in order to forecast future outbreaks in Bentiu IDP camp, and to provide lessons learned for better planning and implementation of prospective vaccination campaigns.